Salem Investment Counselors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.8M Sell
176,284
-385
-0.2% -$89.7K 1.11% 19
2026
Q1
$43.2M Sell
176,669
-1,101
-0.6% -$256K 1.27% 17
2025
Q4
$36.8M Sell
177,770
-586
-0.3% -$116K 1.04% 20
2025
Q3
$33.1M Sell
178,356
-317
-0.2% -$54.3K 0.95% 23
2025
Q2
$27.3M Sell
178,673
-798
-0.4% -$123K 0.87% 23
2025
Q1
$29.8M Sell
179,471
-68
-0% -$10.6K 1.04% 17
2024
Q4
$26M Buy
179,539
+503
+0.3% +$77.9K 0.85% 21
2024
Q3
$29M Sell
179,036
-410
-0.2% -$65.3K 0.87% 21
2024
Q2
$26.2M Buy
179,446
+917
+0.5% +$136K 0.85% 23
2024
Q1
$28.2M Buy
178,529
+4,050
+2% +$645K 0.93% 22
2023
Q4
$27.3M Buy
174,479
+2,755
+2% +$422K 0.94% 19
2023
Q3
$26.7M Sell
171,724
-5,275
-3% -$870K 1.02% 16
2023
Q2
$29.3M Buy
176,999
+1,526
+0.9% +$246K 1.06% 15
2023
Q1
$27.2M Buy
175,473
+6,202
+4% +$1M 1.09% 15
2022
Q4
$29.9M Buy
169,271
+2,129
+1% +$368K 1.28% 9
2022
Q3
$27.3M Buy
167,142
+1,933
+1% +$327K 1.24% 9
2022
Q2
$29.3M Buy
165,209
+2,350
+1% +$419K 1.34% 9
2022
Q1
$28.9M Buy
162,859
+1,093
+0.7% +$186K 1.13% 13
2021
Q4
$27.7M Buy
161,766
+861
+0.5% +$141K 0.96% 16
2021
Q3
$26M Buy
160,905
+3,965
+3% +$676K 1.42% 15
2021
Q2
$25.9M Sell
156,940
-372
-0.2% -$61.6K 1.42% 16
2021
Q1
$25.9M Buy
157,312
+1,364
+0.9% +$221K 1.58% 14
2020
Q4
$24.5M Buy
155,948
+1,352
+0.9% +$200K 1.62% 12
2020
Q3
$23M Buy
154,596
+131
+0.1% +$19.4K 1.76% 11
2020
Q2
$21.7M Sell
154,465
-659
-0.4% -$96K 1.84% 11
2020
Q1
$20.3M Buy
155,124
+1,205
+0.8% +$171K 2.1% 9
2019
Q4
$22.5M Buy
153,919
+797
+0.5% +$108K 1.86% 10
2019
Q3
$19.8M Buy
153,122
+435
+0.3% +$57.3K 1.82% 11
2019
Q2
$21.3M Sell
152,687
-9,860
-6% -$1.36M 1.96% 9
2019
Q1
$22.5M Buy
162,547
+5,826
+4% +$780K 2.29% 9
2018
Q4
$20.2M Sell
156,721
-5,826
-4% -$813K 2.55% 9
2018
Q3
$22.5M Buy
162,547
+1,297
+0.8% +$172K 2.29% 9
2018
Q2
$19.6M Sell
161,250
-12,713
-7% -$1.59M 1.79% 10
2018
Q1
$22M Sell
173,963
-72
-0% -$9.73K 2.48% 9
2017
Q4
$24.3M Sell
174,035
-1,234
-0.7% -$172K 2.63% 8
2017
Q3
$23M Sell
175,269
-11,230
-6% -$1.49M 2.68% 7
2017
Q2
$24.7M Buy
186,499
+11,079
+6% +$1.41M 2.86% 6
2017
Q1
$21.8M Buy
175,420
+1,898
+1% +$227K 2.33% 7
2016
Q4
$20M Buy
173,522
+4,831
+3% +$558K 2.29% 6
2016
Q3
$199K Sell
168,691
-5,114
-3% -$620K 2.6% 4
2016
Q2
$21.1M Buy
173,805
+4,456
+3% +$506K 2.53% 6
2016
Q1
$18.3M Sell
169,349
-7,485
-4% -$775K 2.27% 6
2015
Q4
$18.2M Sell
176,834
-1,385
-0.8% -$139K 2.3% 6
2015
Q3
$16.5M Sell
178,219
-481
-0.3% -$46.5K 2.16% 8
2015
Q2
$17.4M Sell
178,700
-1,297
-0.7% -$130K 2.12% 7
2015
Q1
$18.1M Buy
179,997
+39
+0% +$3.97K 2.16% 7
2014
Q4
$18.8M Sell
179,958
-516
-0.3% -$54.4K 2.24% 6
2014
Q3
$19.2M Sell
180,474
-284
-0.2% -$29.5K 2.31% 5
2014
Q2
$18.9M Sell
180,758
-1,590
-0.9% -$161K 2.3% 6
2014
Q1
$17.9M Buy
182,348
+786
+0.4% +$72.9K 2.22% 5
2013
Q4
$16.6M Sell
181,562
-812
-0.4% -$74.8K 2.17% 7
2013
Q3
$15.8M Sell
182,374
-5,503
-3% -$494K 2.2% 5
2013
Q2
$16.1M Buy
+187,877
New +$15.9M 2.33% 5

Other funds holding JNJ

Salem Investment Counselors's JNJ Position: Q2 2026 in Review

Salem Investment Counselors reduced its Johnson & Johnson (JNJ) stake by 0.22% in Q2 2026, selling an estimated $89.7K and leaving 176,284 shares worth $44.8M. The position accounts for 1.11% of the portfolio, ranked #19.

Salem Investment Counselors first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. 2,510 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Salem Investment Counselors held 176,284 shares of Johnson & Johnson worth $44.8M as of Q2 2026.
  • Salem Investment Counselors sold 385 Johnson & Johnson shares in Q2 2026, an estimated $89.7K.
  • Johnson & Johnson made up 1.11% of Salem Investment Counselors's portfolio in Q2 2026, its #19 holding.
  • Salem Investment Counselors first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • 2,510 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.